Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC) Post navigation Previous: Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma GrowthNext: Quality of Life Changes in Patients with Alport Syndrome: Results from the ATHENA Study
